TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06542939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated CHW Intervention
Description: Participants will undergo all 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources. There will be two one-on-one virtual meetings, up to 9 follow-up phone calls to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHW Session 1 Only
Description: Participants will attend only the first group-based health education session on hypertension and diabetes management.
Study: NCT05912816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48 Combined With Tislelizumab
Description: In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour.
Study: NCT06040203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)
Description: Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)
Description: Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline solution)
Description: Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
Study: NCT04999007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence algorithm
Description: Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
Study: NCT05971979

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04794972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-039
Description: Administration by intravenous infusion.
Study: NCT04975217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo FMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation Capsule
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo standard of care resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Colonoscopy
Description: Undergo colonoscopy
Study: NCT05188066

Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: Collect the placenta and fetal membranes and perfor either tissue culture or fixation for further analyses

Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: Collect the placenta and fetal membranes and perfor either tissue culture or fixation for further analyses
Study: NCT06566339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotically Aligned Eye Imaging System
Description: Robotically Aligned Eye Imaging System is a non-contact, micrometer scale imaging technique that provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D. The study team will develop hardware systems and software algorithms necessary for acquiring ocular anterior segment images for those seeking eye care in emergency department settings.
Study: NCT05866536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin
Description: 2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: 2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
Study: NCT05136066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with peppermint oil
Description: Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
Study: NCT06341959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral screening
Description: The participants in the intervention group will receive an oral examination. Subsequently, information about any identified problem will be given. Lastly, participants will receive a referral letter for their dentist and a report for the general practitioner. If the participants don't have a regular dentist, they will also be given a list with contact information of dentists in the area.
Study: NCT05364840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: Orally available protease inhibitor capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product capsule
Study: NCT05125224

Intervention type: DRUG
Intervention: Dihydropyridine calcium channel blocker
Description: Dihydropyridine calcium channel blocker claim is used as the exposure group.

Intervention type: DRUG
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide claim is used as the reference group.
Study: NCT06031116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: depigmentation
Description: gingival depigmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: depigmentation
Description: gingival depigmentation
Study: NCT04415775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game based treadmill Program
Description: Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Gait Rehabilitation
Description: Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
Study: NCT06086067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic session
Description: This session will consist of an aerobic training session performed on a cycle ergometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic session
Description: This session will consist of an aerobic training session performed on a cycle ergometer.
Study: NCT05454709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Use of dasiglucagon in the AP system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucaGen
Description: Use of GlucaGen in the AP system.
Study: NCT04945304

Intervention type: PROCEDURE
Intervention: magnetic bariatric surgery
Description: Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance

Intervention type: PROCEDURE
Intervention: Magnetic gastric bypass
Description: Using the magnetic assistance to perform a gastric bypass
Study: NCT05863806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilzation
Description: Participants were instructed that MWM, including shoulder movement, must be pain-free and should be immediately stopped if any pain is experienced during the treatment.~The single session of MWM technique was last around 20 minutes, in 3 sets of 10 repetitions with a rest interval of 30 seconds between each sets.
Study: NCT05816642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib or pazopanib
Description: Single targeted therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined with axitinib
Description: targeted therapy combined with immunotherapy
Study: NCT04853693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom´s Supporting Mom
Description: A preventive peer consultation intervention for Postpartum Depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment As Usual
Description: Referral to treatment in the community, clinical monitoring
Study: NCT04860895

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AP-23
Description: AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
Study: NCT05700994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Contingency Management
Description: Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals)
Study: NCT05863806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trasverse Friction Massage
Description: Deep friction massage was given to rotator cuff tendon with the tip of index finger, which is reinforced by middle finger.~It was given in transverse direction for 10 - 12 minutes. Transverse friction massage was Given twice a week with the gap of days for the first 3 week and then the repetition is increased to 3 to 4 times a week for the rest of duration.
Study: NCT05201248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)
Study: NCT05068557

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary plan along with chia/linseed oil capsules (3 capsules daily. Containing ALA 1.6 g).
Description: Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: ALA 1.6 g).
Study: NCT05201248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral; Capsule
Study: NCT05264441

Intervention type: DEVICE
Group type: OTHER
Intervention: In-Check DIAL G16
Description: Patients will inspire into an In-Check DIAL G16 device.
Study: NCT05700994

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Contingency Management
Description: Participants allocated to standard of care contingency management will receive incentives for peer encounters.
Study: NCT05223686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19-CD22 Targeted T Cells Injection
Description: One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.
Study: NCT04748068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-Fr Glidesheath Slender
Description: The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cordis 7-Fr radial sheath
Description: Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
Study: NCT05908370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
Description: Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
Study: NCT05036382

Intervention type: BEHAVIORAL
Intervention: Steps data observation
Description: Sending more step data from the experimental group that received the incentive message
Study: NCT05981079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: Piperacillin Sodium and Tazobactam Sodium for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Description: Piperacillin Sodium and Tazobactam Sodium for Injection
Study: NCT06201793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: Minocycline is a tetracycline antibiotic medication used to treat a number of bacterial infections such as pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis.
Study: NCT05472389

Intervention type: OTHER
Group type: OTHER
Intervention: Video-electroencephalography
Description: All patients will be monitored 24 hours. Whenever possible, duration of the long-term monitoring will be extended to 48 hours, including a second full night polysomnography. These recordings will also allow us to assess sleep architecture and to capture seizures in some patients video , EEEG, EKG, respiration and other polysomnography data will be centralized at Hospices Civils de Lyon. A copy of the EEG-EKG data required to address the objectives related to cardiac features will then be electronically transferred to Partner 2 (Bonn) Evaluation will be performed blind to other data by the Partner 1 (Lyon) for the respiratory data and by the Partner 2 (Bonn) for the EKG data All primary outcomes and secondary outcomes will be assessed with respect to duration of epilepsy and frequency of convulsive seizures during the baseline period.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Samples
Description: Blood samples will be collected at V2 in all patients. A total of seven blood samples of 4 ml each will be collected, including five EDTA and two dry. Samples EDTA plasma and serum will then be prepared after centrifugation. In children \< 10 kg, only 5 samples of 4 ml each (22 ml in total), including four EDTA and one dry.
Study: NCT05177484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral ferric maltol
Description: The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.
Study: NCT05079295

Intervention type: PROCEDURE
Intervention: CSDH evacuation
Description: Burr hole for chronic subdural hematomas

Intervention type: PROCEDURE
Intervention: CSDH evacuation
Description: Burr hole for chronic subdural hematomas
Study: NCT04741061

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sputnik Light
Description: Sputnik-Light vector vaccine:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05907304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naporafenib
Description: Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
Study: NCT05756374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OUT to IN
Description: OUT to IN comprises 20 body-oriented biweekly 40-minute sessions facilitated by a psychomotor therapist in a pedagogical partnership with the preschool teacher. Sessions are implemented outdoors. All sessions are framed in a context of freedom and self and mutual bodily resonance, according to the following structure: First, children are invited to engage in exercise play activities. Second, children engage in ludic relaxation proposals. Finally, children are asked to reflect on their bodily experiences and express themselves through different expressive mediators. Preschool teachers also participate in a 25-hour training focused on the underlying principles of OUT to In and participate in 20 body-oriented biweekly 20-minute relaxation sessions, facilitated by a psychomotor therapist.
Study: NCT05181423

Intervention type: OTHER
Intervention: Biomarkers
Description: Different serum and radiological biomarkers neonates undergoing abdominal surgery.

Intervention type: OTHER
Intervention: Biomarkers
Description: Different serum and radiological biomarkers neonates undergoing abdominal surgery.
Study: NCT04857515

Intervention type: DEVICE
Intervention: Clickotine®
Description: Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.

Intervention type: DEVICE
Intervention: Clickotine®
Description: Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
Study: NCT05377918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: spiritual diary group and diary gruop will write a diary

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: spiritual diary group and diary gruop will write a diary
Study: NCT04789759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socket Preservation - Bond Apatite synthetic bone substitute
Description: Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth. If 1/3 of the buccal plate is missing, considered a class 2 alveolar socket.~Extraction of tooth and place 2/3 biphasic calcium sulfate cement matrix's with Hydroxyapatite (HA granules) , condensed , and covered with a resorbable membrane suture to the adjacent tissue.~At implant placement ,take bone for histological preparation and histomorphometric analysis of the healing pattern.~At T0, T1 and T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements, will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.~Primary and secondary stability will be measured by ISQ units with a RFA machine, that will include the machine to measure and the magnetic tip to be screwed in the implant platform.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket healing - No Filler
Description: Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth, at extraction day, no flap opening , atraumatic extraction, no biomaterial filler, At T0, T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements will include an intramural scanner from all the stages , we will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.
Study: NCT06250868

Intervention type: DEVICE
Intervention: Kerato-Refracto Tonometer
Description: measures pressure inside the eye and thickness of the cornea.
Study: NCT05494866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat Oral Tablet
Description: Cobicistat Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabin
Description: Gemcitabin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: nab-Paclitaxel
Study: NCT05559645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Daily dosing of DZD9008 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Daily dosing of DZD9008 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Daily dosing of DZD9008 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Daily dosing of DZD9008 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Daily dosing of DZD9008 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Daily dosing of DZD9008 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: Daily dosing of DZD9008 300mg